Emerald Mutual Fund Advisers Trust’s Cytokinetics CYTK Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23.8M	Buy	279,769 +144,305	+107%	+$10.4M	0.84%	47
2026 Q1	$8.93M	Buy	+135,464	New	+$8.61M	0.43%	89
2024 Q2	–	Sell	-72,080	Closed	-$5.05M	–	228
2024 Q1	$5.05M	Buy	+72,080	New	+$5.57M	0.26%	106
2023 Q2	–	Sell	-192,097	Closed	-$6.76M	–	255
2023 Q1	$6.76M	Sell	192,097 -178,902	-48%	-$7.3M	0.4%	93
2022 Q4	$17M	Buy	370,999 +79,096	+27%	+$3.4M	1.05%	38
2022 Q3	$14.1M	Buy	291,903 +165,324	+131%	+$7.96M	0.89%	44
2022 Q2	$4.97M	Buy	+126,579	New	+$5.1M	0.29%	103

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust's CYTK Position: Q2 2026 in Review

Emerald Mutual Fund Advisers Trust increased its Cytokinetics (CYTK) stake by 107% in Q2 2026, buying an estimated $10.4M and bringing the position to 279,769 shares worth $23.8M. The position accounts for 0.84% of the portfolio, ranked #47.

Emerald Mutual Fund Advisers Trust first reported a position in CYTK in Q2 2022 and has held it in 7 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Emerald Mutual Fund Advisers Trust held 279,769 shares of Cytokinetics worth $23.8M as of Q2 2026.
Emerald Mutual Fund Advisers Trust bought 144,305 Cytokinetics shares in Q2 2026, an estimated $10.4M.
Cytokinetics made up 0.84% of Emerald Mutual Fund Advisers Trust's portfolio in Q2 2026, its #47 holding.
Emerald Mutual Fund Advisers Trust first reported a position in Cytokinetics in Q2 2022 and has held it in 7 quarters since.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q2 2026, filed 5 Aug 2026.